March 22, 2017

FACIT Launches The Prospects Oncology Fund

New evergreen fund to help Ontario discoveries reach seed-stage funding faster

Prospects Fund LogoTORONTO, March 21, 2017 /CNW/ – Fight Against Cancer Innovation Trust (“FACIT”) is pleased to announce the launch of The Prospects Oncology Fund (“Prospects Fund”), designed to advance early-stage Ontario cancer discoveries by supporting the proof-of-concept studies needed to attract seed-stage investment. Managed by FACIT, this is an evergreen fund to which capital is allocated annually.

Continue reading – FACIT Launches The Prospects Oncology Fund

March 22, 2017

FACIT Announces Investment in Propellon Therapeutics

Seed financing of CAD$3.0M positions first-in-class WDR5 cancer therapy for clinical development

TORONTO, March 22, 2017 /CNW/ – FACIT announced a seed stage investment in Propellon Therapeutics (the “Company” or “Propellon”), a start-up created by FACIT focused on developing a portfolio of WDR5-targeted anti-cancer therapeutics. FACIT’s investment, combined with non-dilutive capital, achieves a targeted $3.0M financing for the lead program. The seed funding enables Propellon to accelerate the nomination of a candidate drug and position the Company for financing and/or entering a strategic partnership for clinical trials in patients with haematological cancers.

Continue reading – FACIT Announces Investment in Propellon Therapeutics

March 9, 2017

Innovative technique greatly increases sensitivity of DNA sequencing

Dr. Paul Krzyzanowski

New molecular barcode technology reduces error rate in genomic sequencing to 1 in 10,000

Toronto (March 9, 2017) – Researchers at the Ontario Institute for Cancer Research (OICR), together with international collaborators, have invented a technique to avoid a major problem with common laboratory techniques and improve the sensitivity of important cancer tests.

Continue reading – Innovative technique greatly increases sensitivity of DNA sequencing

February 23, 2017

New Gene Sequencing Software Could Aid in Early Detection, Treatment of Cancer

A closeup of the nanopore sequencing device

Digital Detection Tool Will Be Shared Freely Over the Web

Toronto, ON and Baltimore, MD (February 23, 2017) A research team from the United States and Canada has developed and successfully tested new computational software that determines whether a human DNA sample includes an epigenetic add-on linked to cancer and other adverse health conditions.

Continue reading – New Gene Sequencing Software Could Aid in Early Detection, Treatment of Cancer

February 23, 2017

FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation

 

OICR and FACIT logosFinancing leverages and strengthens Ontario’s next-generation radiotherapeutics expertise, products

TORONTO, ON (February 23, 2017) – The Fight Against Cancer Innovation Trust (FACIT) and the Ontario Institute for Cancer Research (OICR) are pleased to report that Fusion Pharmaceuticals Inc. (Fusion) has closed a US$25M Series A financing, with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as the lead investor. Additional, new investors include venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well as founding investor FACIT.

Continue reading – FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation

February 10, 2017

OICR researchers to be part of Cancer Research UK’s Grand Challenge helping to answer cancer’s biggest questions

Technology and DNA

Toronto (February 10, 2017) – Ontario Institute for Cancer Research (OICR) researchers Drs. Lincoln Stein and Steven Gallinger have been announced as members of one of the first global research teams to be recipients of Cancer Research UK’s Grand Challenge.

The Grand Challenge aims to help overcome the biggest challenges facing cancer research in a global effort to beat cancer sooner.

Stein and Gallinger’s pioneering team will study samples from five continents to understand the DNA damage associated with different cancers, to understand what causes them and if they can be prevented. The project will be led by Professor Mike Stratton at the Wellcome Trust Sanger Institute, Cambridge, with collaborators from France, the U.S. and U.K.

Continue reading – OICR researchers to be part of Cancer Research UK’s Grand Challenge helping to answer cancer’s biggest questions

January 9, 2017

Scientists identify DNA signature linked to prostate cancer severity

Findings published in renowned journal Nature

January 9, 2017 – TORONTO, ON – The Canadian Prostate Cancer Genome Network (CPC-GENE) has published findings from the world’s most comprehensive genetic analysis of prostate cancer tumours in the journal Nature. Led by Drs. Robert Bristow of the Princess Margaret Cancer Centre and Paul Boutros of the Ontario Institute for Cancer Research, CPC-GENE has uncovered the full set of mutations that can occur in the most common cancer in men. By fully cataloging these mutations, the CPC-GENE team was able to create a new signature that predicts at an early stage whether a prostate cancer tumour will become aggressive or not, allowing for personalized treatment.

Continue reading – Scientists identify DNA signature linked to prostate cancer severity

November 2, 2016

FACIT start-up Turnstone Biologics closes USD $41M financing

OrbiMed, Versant-led round continues commercialization success for Turnstone’s cancer therapies

John Bell and contributorsTORONTO, Nov. 2, 2016 /CNW/ – Turnstone Biologics Inc. (“Turnstone”), an Ontario-based developer of novel oncolytic viral immunotherapies, announced the closing of a USD $41.4 million Series B financing led by OrbiMed Advisors LLC (“OrbiMed”) and Versant Ventures (“Versant”), which led Turnstone’s Series A round in October 2015. New investor F-Prime Capital Partners (“F-Prime”) and existing founding investor FACIT also participated. Proceeds from the financing will support an ongoing Phase I/II clinical trial in patients with advanced or metastatic solid tumours as well as accelerate and expand Turnstone’s pipeline, funding the development of three additional programs into the clinic. In connection with the financing Orbimed’s Rishi Gupta, JD and F-Prime’s Ben Auspitz will join Turnstone’s board of directors alongside Versant’s Brad Bolzon, PhD and Jerel Davis, PhD as well as FACIT’s Jeff Courtney.

Continue reading – FACIT start-up Turnstone Biologics closes USD $41M financing

October 12, 2016

New findings challenge current view of how pancreas cancer develops

Dr. Faiyaz Notta and Dr. Steven Gallinger

The findings provide important insights into how pancreas cancer develops and spreads and new strategies for better understanding one of the mostly deadly types of cancer.

Toronto (October 12, 2016) – Researchers in the multidisciplinary PanCuRx research initiative at the Ontario Institute for Cancer Research (OICR) and University Health Network’s Princess Margaret Cancer Centre, led by Dr. Faiyaz Notta and Dr. Steven Gallinger, today published new findings that challenge current beliefs about how and why pancreas cancer is so aggressive.

Continue reading – New findings challenge current view of how pancreas cancer develops

October 6, 2016

Reactome announces annotation and release of 10,000th human protein

Reactome - Graphic announcing the 10,000th human protein annotated

The data are being shared with the wider biological research community to help in the development of new therapies for diseases like cancer.

Toronto (October 6, 2016) – The European Bioinformatics Institute (EMBL-EBI), the New York University School of Medicine and the Ontario Institute for Cancer Research (OICR) today announced a major milestone in the Reactome project: the annotation and release of its 10,000th human protein, making it the most comprehensive open access pathway knowledgebase available to the scientific community.

Continue reading – Reactome announces annotation and release of 10,000th human protein

August 17, 2016

New retrospective study aims to identify mutations to better diagnose breast cancer in the future

Toronto (August 17, 2016) – Mr. Peter Goodhand, President of The Ontario Institute for Cancer Research (OICR), today announced a new collaborative research study in partnership with Thermo Fisher Scientific and Queen’s University to help bring more targeted diagnosis and treatment to breast cancer patients in the future.

Continue reading – New retrospective study aims to identify mutations to better diagnose breast cancer in the future

July 14, 2016

International team launches community competition to unravel how cancer changes a cell’s RNA

Logos of the Challenge partners

An open challenge that merges the efforts of the International Cancer Genome Consortium, The Cancer Genome Atlas, and the NCI Cloud Pilots with Sage Bionetworks and the open science DREAM Challenge community

Continue reading – International team launches community competition to unravel how cancer changes a cell’s RNA